GH Research plc reports Phase 2b trial of GH001 meets primary endpoint in treatment-resistant depression

Reuters11-06

GH Research plc reports Phase 2b trial of GH001 meets primary endpoint in treatment-resistant depression

GH Research plc reported a net loss of $14.0 million, or $0.23 per share, for the quarter ended September 30, 2025, compared to a net loss of $12.1 million, or $0.23 per share, for the same quarter in 2024. Research and development expenses rose to $10.6 million from $8.4 million, primarily due to increased technical development and employee expenses, partially offset by lower clinical development expenses. General and administrative expenses increased to $6.0 million from $4.2 million, mainly due to higher professional fees and employee expenses. Cash, cash equivalents and marketable securities were $293.9 million as of September 30, 2025, up from $182.6 million at the end of 2024. During the quarter, GH Research reported the full dataset from its Phase 2b clinical trial of GH001 in treatment-resistant depression and presented long-term safety and efficacy data from its Open-Label Extension at the ECNP Congress. The company continues to expect to initiate its global pivotal program in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570383-en) on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581906273?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581906273","market":"us","top_or_hot":-1,"title":"GH Research plc reports Phase 2b trial of GH001 meets primary endpoint in treatment-resistant depression","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      GH Research plc reports Phase 2b trial of GH001 meets primary endpoint in treatment-resistant depression\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        GH Research plc reported a net loss of $14.0 million, or $0.23 per share, for the quarter ended September 30, 2025, compared to a net loss of $12.1 million, or $0.23 per share, for the same quarter in 2024. Research and development expenses rose to $10.6 million from $8.4 million, primarily due to increased technical development and employee expenses, partially offset by lower clinical development expenses. General and administrative expenses increased to $6.0 million from $4.2 million, mainly due to higher professional fees and employee expenses. Cash, cash equivalents and marketable securities were $293.9 million as of September 30, 2025, up from $182.6 million at the end of 2024. During the quarter, GH Research reported the full dataset from its Phase 2b clinical trial of GH001 in treatment-resistant depression and presented long-term safety and efficacy data from its Open-Label Extension at the ECNP Congress. The company continues to expect to initiate its global pivotal program in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570383-en) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research plc reports Phase 2b trial of GH001 meets primary endpoint in treatment-resistant depression</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research plc reports Phase 2b trial of GH001 meets primary endpoint in treatment-resistant depression\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      GH Research plc reports Phase 2b trial of GH001 meets primary endpoint in treatment-resistant depression\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        GH Research plc reported a net loss of $14.0 million, or $0.23 per share, for the quarter ended September 30, 2025, compared to a net loss of $12.1 million, or $0.23 per share, for the same quarter in 2024. Research and development expenses rose to $10.6 million from $8.4 million, primarily due to increased technical development and employee expenses, partially offset by lower clinical development expenses. General and administrative expenses increased to $6.0 million from $4.2 million, mainly due to higher professional fees and employee expenses. Cash, cash equivalents and marketable securities were $293.9 million as of September 30, 2025, up from $182.6 million at the end of 2024. During the quarter, GH Research reported the full dataset from its Phase 2b clinical trial of GH001 in treatment-resistant depression and presented long-term safety and efficacy data from its Open-Label Extension at the ECNP Congress. The company continues to expect to initiate its global pivotal program in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570383-en) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL86jM74:1","article_id":"2581906273","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581906273","pubTimestamp":1762430561,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"GH Research plc reported a net loss of $14.0 million, or $0.23 per share, for the quarter ended September 30, 2025, compared to a net loss of $12.1 million, or $0.23 per share, for the same quarter in 2024. Research and development expenses rose to $10.6 million from $8.4 million, primarily due to increased technical development and employee expenses, partially offset by lower clinical development expenses. General and administrative expenses increased to $6.0 million from $4.2 million, mainly due to higher professional fees and employee expenses. Cash, cash equivalents and marketable securities were $293.9 million as of September 30, 2025, up from $182.6 million at the end of 2024. During the quarter, GH Research reported the full dataset from its Phase 2b clinical trial of GH001 in treatment-resistant depression and presented long-term safety and efficacy data from its Open-Label Extension at the ECNP Congress. The company continues to expect to initiate its global pivotal program in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4007":"制药","GHRS":"GH Research PLC","BK4588":"碎股","BK4539":"次新股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所"},"translate_title":"GH Research plc报告GH001的2b期试验达到了治疗难治性抑郁症的主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"GHRS":0.9},"content_text":"GH Research plc reports Phase 2b trial of GH001 meets primary endpoint in treatment-resistant depression\n    \n\n        GH Research plc reported a net loss of $14.0 million, or $0.23 per share, for the quarter ended September 30, 2025, compared to a net loss of $12.1 million, or $0.23 per share, for the same quarter in 2024. Research and development expenses rose to $10.6 million from $8.4 million, primarily due to increased technical development and employee expenses, partially offset by lower clinical development expenses. General and administrative expenses increased to $6.0 million from $4.2 million, mainly due to higher professional fees and employee expenses. Cash, cash equivalents and marketable securities were $293.9 million as of September 30, 2025, up from $182.6 million at the end of 2024. During the quarter, GH Research reported the full dataset from its Phase 2b clinical trial of GH001 in treatment-resistant depression and presented long-term safety and efficacy data from its Open-Label Extension at the ECNP Congress. The company continues to expect to initiate its global pivotal program in 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570383-en) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581906273","isCrawlerRequest":true}